{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:15:57Z","timestamp":1782954957078,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00246208, NRF-2021R1A6A3A13042153"],"award-info":[{"award-number":["RS-2023-00246208, NRF-2021R1A6A3A13042153"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R111A3060512"],"award-info":[{"award-number":["2021R111A3060512"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00249115"],"award-info":[{"award-number":["RS-2023-00249115"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003705","name":"Korea Institute of Toxicology","doi-asserted-by":"publisher","award":["1711159826"],"award-info":[{"award-number":["1711159826"]}],"id":[{"id":"10.13039\/501100003705","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["grant no. 22213MFDS391"],"award-info":[{"award-number":["grant no. 22213MFDS391"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder characterized by joint destruction due to synovial hypertrophy and the infiltration of inflammatory cells. Despite substantial progress in RA treatment, challenges persist, including suboptimal treatment responses and adverse effects associated with current therapies. This study investigates the anti-rheumatic capabilities of the newly identified multi-protein kinase inhibitor, KMU-11342, aiming to develop innovative agents targeting RA. In this study, we synthesized the novel multi-protein kinase inhibitor KMU-11342, based on indolin-2-one. We assessed its cardiac electrophysiological safety using the Langendorff system in rat hearts and evaluated its toxicity in zebrafish in vivo. Additionally, we examined the anti-rheumatic effects of KMU-11342 on human rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), THP-1 cells, and osteoclastogenesis in RAW264.7 cells. KMU-11342 demonstrated the ability to inhibit LPS-induced chemokine inhibition and the upregulation of pro-inflammatory cytokines, cyclooxygenase-2, inducible nitric oxide synthase, p-IKK\u03b1\/\u03b2, p-NF-\u03baB p65, and the nuclear translocation of NF-\u03baB p65 in RA-FLS. It effectively suppressed the upregulation of NLR family pyrin domain containing 3 (NLRP3) and caspase-1 cleavage. Furthermore, KMU-11342 hindered the activation of osteoclast differentiation factors such as RANKL-induced TRAP, cathepsin K, NFATc-1, and c-Fos in RAW264.7 cells. KMU-11342 mitigates LPS-mediated inflammatory responses in THP-1 cells by inhibiting the activation of NLRP3 inflammasome. Notably, KMU-11342 exhibited minimal cytotoxicity in vivo and electrophysiological cardiotoxicity ex vivo. Consequently, KMU-11342 holds promise for development as a therapeutic agent in RA treatment.<\/jats:p>","DOI":"10.1007\/s00011-024-01904-6","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T16:01:58Z","timestamp":1718467318000},"page":"1371-1391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-rheumatic property and physiological safety of KMU-11342 in in vitro and in vivo models"],"prefix":"10.1007","volume":"73","author":[{"given":"Hye Suk","family":"Baek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Sukbong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunsu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunju","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungik","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunho","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Wook","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeg Kyu","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Nam","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Suk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"key":"1904_CR1","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. https:\/\/doi.org\/10.1038\/nrdp.2018.1","journal-title":"Nat Rev Dis Primers"},{"key":"1904_CR2","doi-asserted-by":"publisher","unstructured":"Fang Q, Zhou C, Nandakumar KS. Molecular and cellular pathways contributing to joint damage in rheumatoid arthritis. Mediators Inflamm. 2020;2020:3830212. https:\/\/doi.org\/10.1155\/2020\/3830212","DOI":"10.1155\/2020\/3830212"},{"key":"1904_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12248","volume":"176","author":"H Patterson","year":"2014","unstructured":"Patterson H, Nibbs R, McInnes I, Siebert S. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clin Exp Immunol. 2014;176:1\u201310. https:\/\/doi.org\/10.1111\/cei.12248","journal-title":"Clin Exp Immunol"},{"key":"1904_CR4","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","volume":"20","author":"P Cohen","year":"2021","unstructured":"Cohen P, Cross D, J\u00e4nne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021;20:551\u201369. https:\/\/doi.org\/10.1038\/s41573-021-00195-4","journal-title":"Nat Rev Drug Discov"},{"key":"1904_CR5","doi-asserted-by":"publisher","unstructured":"Siccardi AJ 3rd, Garris HW, Jones WT, Moseley DB, D\u2019Abramo LR, Watts SA. Growth and survival of zebrafish (Danio rerio) fed different commercial and laboratory diets. Zebrafish. 2009;6:275\u201380. https:\/\/doi.org\/10.1089\/zeb.2008.0553","DOI":"10.1089\/zeb.2008.0553"},{"key":"1904_CR6","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/eurheartj\/ehy365","volume":"40","author":"P Ferdinandy","year":"2019","unstructured":"Ferdinandy P, Baczko I, Bencsik P, Giricz Z, Gorbe A, Pacher P, et al. Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. Eur Heart J. 2019;40:1771\u20137. https:\/\/doi.org\/10.1093\/eurheartj\/ehy365","journal-title":"Eur Heart J"},{"key":"1904_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.vascn.2009.05.008","volume":"60","author":"K Norton","year":"2009","unstructured":"Norton K, Iacono G, Vezina M. Assessment of the pharmacological effects of inotropic drugs on left ventricular pressure and contractility: an evaluation of the QA interval as an indirect indicator of cardiac inotropism. J Pharmacol Toxicol Methods. 2009;60:193\u20137. https:\/\/doi.org\/10.1016\/j.vascn.2009.05.008","journal-title":"J Pharmacol Toxicol Methods"},{"key":"1904_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nrd.2016.21","volume":"15","author":"K Chaudhari","year":"2016","unstructured":"Chaudhari K, Rizvi S, Syed BA. Rheumatoid arthritis: current and future trends. Nat Rev Drug Discov. 2016;15:305\u20136. https:\/\/doi.org\/10.1038\/nrd.2016.21","journal-title":"Nat Rev Drug Discov"},{"key":"1904_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","volume":"6","author":"Q Guo","year":"2018","unstructured":"Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15. https:\/\/doi.org\/10.1038\/s41413-018-0016-9","journal-title":"Bone Res"},{"key":"1904_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1517\/13543776.2016.1118059","volume":"26","author":"A Leoni","year":"2016","unstructured":"Leoni A, Locatelli A, Morigi R, Rambaldi M. 2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008\u20132014). Expert Opin Ther Pat. 2016;26:149\u201373. https:\/\/doi.org\/10.1517\/13543776.2016.1118059","journal-title":"Expert Opin Ther Pat"},{"key":"1904_CR11","doi-asserted-by":"publisher","unstructured":"Baek HS, Min HJ, Hong VS, Kwon TK, Park JW, Lee J, et al. Anti-inflammatory effects of the novel PIM kinase inhibitor KMU-470 in RAW 264.7 cells through the TLR4-NF-kappaB-NLRP3 pathway. Int J Mol Sci. 2020;21. https:\/\/doi.org\/10.3390\/ijms21145138","DOI":"10.3390\/ijms21145138"},{"key":"1904_CR12","doi-asserted-by":"publisher","unstructured":"Baek HS, Hong VS, Kim SH, Lee J, Kim S. KMU-1170, a novel multi-protein kinase inhibitor, Suppresses inflammatory signal transduction in THP-1 cells and human osteoarthritic fibroblast-like synoviocytes by suppressing activation of NF-kappaB and NLRP3 inflammasome signaling pathway. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22031194","DOI":"10.3390\/ijms22031194"},{"key":"1904_CR13","doi-asserted-by":"publisher","first-page":"114258","DOI":"10.1016\/j.biopha.2023.114258","volume":"159","author":"JY Hsu","year":"2023","unstructured":"Hsu JY, Hsu KC, Sun C, Chou CH, Lin TE, Sung TY, et al. Design, synthesis, and biological evaluation of indolin-2-one derivatives as novel cyclin-dependent protein kinase 8 (CDK8) inhibitors. Biomed Pharmacother. 2023;159:114258. https:\/\/doi.org\/10.1016\/j.biopha.2023.114258","journal-title":"Biomed Pharmacother"},{"key":"1904_CR14","doi-asserted-by":"publisher","unstructured":"Pan T, He M, Deng L, Li J, Fan Y, Hao X, et al. Design, synthesis, and evaluation of the COX-2 inhibitory activities of New 1,3-Dihydro-2H-indolin-2-one derivatives. Molecules. 2023;28. https:\/\/doi.org\/10.3390\/molecules28124668","DOI":"10.3390\/molecules28124668"},{"key":"1904_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1021\/acs.chemrestox.9b00387","volume":"33","author":"SD Lamore","year":"2020","unstructured":"Lamore SD, Kohnken RA, Peters MF, Kolaja KL. Cardiovascular toxicity induced by kinase inhibitors: mechanisms and preclinical approaches. Chem Res Toxicol. 2020;33:125\u201336. https:\/\/doi.org\/10.1021\/acs.chemrestox.9b00387","journal-title":"Chem Res Toxicol"},{"key":"1904_CR16","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013\u201322. https:\/\/doi.org\/10.1056\/NEJMra032426","journal-title":"N Engl J Med"},{"key":"1904_CR17","unstructured":"Guideline IHT. The non-clinical evaluation of the potential for delayed ventricular repolarization (Qt interval prolongation) by human pharmaceuticals. S7B (http:\/\/www.ich.org\/products\/guidelines\/safety\/article\/safety-guidelines.html) 2005."},{"key":"1904_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/s0008-6363(02)00846-5","volume":"58","author":"WS Redfern","year":"2003","unstructured":"Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32\u201345. https:\/\/doi.org\/10.1016\/s0008-6363(02)00846-5","journal-title":"Cardiovasc Res"},{"key":"1904_CR19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/bs.mcb.2016.10.004","volume":"138","author":"DS Wiley","year":"2017","unstructured":"Wiley DS, Redfield SE, Zon LI. Chemical screening in zebrafish for novel biological and therapeutic discovery. Methods Cell Biol. 2017;138:651\u201379. https:\/\/doi.org\/10.1016\/bs.mcb.2016.10.004","journal-title":"Methods Cell Biol"},{"key":"1904_CR20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nrrheum.2016.61","volume":"12","author":"LA Joosten","year":"2016","unstructured":"Joosten LA, Abdollahi-Roodsaz S, Dinarello CA, O\u2019Neill L, Netea MG. Toll-like receptors and chronic inflammation in rheumatic diseases: new developments. Nat Rev Rheumatol. 2016;12:344\u201357. https:\/\/doi.org\/10.1038\/nrrheum.2016.61","journal-title":"Nat Rev Rheumatol"},{"key":"1904_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11926-009-0051-z","volume":"11","author":"QQ Huang","year":"2009","unstructured":"Huang QQ, Pope RM. The role of toll-like receptors in rheumatoid arthritis. Curr Rheumatol Rep. 2009;11:357\u201364. https:\/\/doi.org\/10.1007\/s11926-009-0051-z","journal-title":"Curr Rheumatol Rep"},{"key":"1904_CR22","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1002\/art.20678","volume":"50","author":"TR Radstake","year":"2004","unstructured":"Radstake TR, Roelofs MF, Jenniskens YM, Oppers-Walgreen B, van Riel PL, Barrera P, et al. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum. 2004;50:3856\u201365. https:\/\/doi.org\/10.1002\/art.20678","journal-title":"Arthritis Rheum"},{"key":"1904_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","volume":"5","author":"T Kawasaki","year":"2014","unstructured":"Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5:461. https:\/\/doi.org\/10.3389\/fimmu.2014.00461","journal-title":"Front Immunol"},{"key":"1904_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.smim.2014.02.009","volume":"26","author":"G Sabio","year":"2014","unstructured":"Sabio G, Davis RJ. TNF and MAP kinase signalling pathways. Semin Immunol. 2014;26:237\u201345. https:\/\/doi.org\/10.1016\/j.smim.2014.02.009","journal-title":"Semin Immunol"},{"key":"1904_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O\u2019Shea","year":"2015","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311\u201328. https:\/\/doi.org\/10.1146\/annurev-med-051113-024537","journal-title":"Annu Rev Med"},{"key":"1904_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.55563\/clinexprheumatol\/1jlh15","volume":"39","author":"Y Ma","year":"2021","unstructured":"Ma Y, Hong FF, Yang SL. Role of prostaglandins in rheumatoid arthritis. Clin Exp Rheumatol. 2021;39:162\u201372. https:\/\/doi.org\/10.55563\/clinexprheumatol\/1jlh15","journal-title":"Clin Exp Rheumatol"},{"key":"1904_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev.pharmtox.011008.145616","volume":"49","author":"T Shimizu","year":"2009","unstructured":"Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol. 2009;49:123\u201350. https:\/\/doi.org\/10.1146\/annurev.pharmtox.011008.145616","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1904_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1172\/jci115591","volume":"89","author":"H Sano","year":"1992","unstructured":"Sano H, Hla T, Maier JA, Crofford LJ, Case JP, Maciag T, et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest. 1992;89:97\u2013108. https:\/\/doi.org\/10.1172\/jci115591","journal-title":"J Clin Invest"},{"key":"1904_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/rheumatology\/35.8.711","volume":"35","author":"RY Kang","year":"1996","unstructured":"Kang RY, Freire-Moar J, Sigal E, Chu CQ. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol. 1996;35:711\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/35.8.711","journal-title":"Br J Rheumatol"},{"key":"1904_CR30","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s000110050362","volume":"47","author":"F Beiche","year":"1998","unstructured":"Beiche F, Brune K, Geisslinger G, Goppelt-Struebe M. Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis. Inflamm Res. 1998;47:482\u20137. https:\/\/doi.org\/10.1007\/s000110050362","journal-title":"Inflamm Res"},{"key":"1904_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1124\/pr.56.3.3","volume":"56","author":"DL Simmons","year":"2004","unstructured":"Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56:387\u2013437. https:\/\/doi.org\/10.1124\/pr.56.3.3","journal-title":"Pharmacol Rev"},{"key":"1904_CR32","doi-asserted-by":"publisher","unstructured":"Huang JB, Chen ZR, Yang SL, Hong FF. Nitric oxide synthases in rheumatoid arthritis. Molecules. 2023;28. https:\/\/doi.org\/10.3390\/molecules28114414","DOI":"10.3390\/molecules28114414"},{"key":"1904_CR33","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1002\/1529-0131(200011)43:11<2501::Aid-anr18>3.0.Co;2-k","volume":"43","author":"G Schett","year":"2000","unstructured":"Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum. 2000;43:2501\u201312. https:\/\/doi.org\/10.1002\/1529-0131(200011)43:11%3C2501::Aid-anr18%3E3.0.Co;2-k","journal-title":"Arthritis Rheum"},{"key":"1904_CR34","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/ni1255","volume":"6","author":"S Sato","year":"2005","unstructured":"Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol. 2005;6:1087\u201395. https:\/\/doi.org\/10.1038\/ni1255","journal-title":"Nat Immunol"},{"key":"1904_CR35","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.it.2013.03.007","volume":"34","author":"AA Ajibade","year":"2013","unstructured":"Ajibade AA, Wang HY, Wang RF. Cell type-specific function of TAK1 in innate immune signaling. Trends Immunol. 2013;34:307\u201316. https:\/\/doi.org\/10.1016\/j.it.2013.03.007","journal-title":"Trends Immunol"},{"key":"1904_CR36","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2174\/1381612824666180327165604","volume":"24","author":"YT Yeung","year":"2018","unstructured":"Yeung YT, Aziz F, Guerrero-Castilla A, Arguelles S. Signaling pathways in inflammation and anti-inflammatory therapies. Curr Pharm Des. 2018;24:1449\u201384. https:\/\/doi.org\/10.2174\/1381612824666180327165604","journal-title":"Curr Pharm Des"},{"key":"1904_CR37","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/1756-185x.12293","volume":"17","author":"LA MacFarlane","year":"2014","unstructured":"MacFarlane LA, Todd DJ. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis. Int J Rheum Dis. 2014;17:359\u201368. https:\/\/doi.org\/10.1111\/1756-185x.12293","journal-title":"Int J Rheum Dis"},{"key":"1904_CR38","doi-asserted-by":"publisher","first-page":"8468","DOI":"10.1021\/jm1004286","volume":"53","author":"ME Flanagan","year":"2010","unstructured":"Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang-Poa C, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010;53:8468\u201384. https:\/\/doi.org\/10.1021\/jm1004286","journal-title":"J Med Chem"},{"key":"1904_CR39","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205\u201319. https:\/\/doi.org\/10.1056\/NEJMra1004965","journal-title":"N Engl J Med"},{"key":"1904_CR40","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.0105-2896.2009.00859.x","volume":"233","author":"B Bartok","year":"2010","unstructured":"Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233:233\u201355. https:\/\/doi.org\/10.1111\/j.0105-2896.2009.00859.x","journal-title":"Immunol Rev"},{"key":"1904_CR41","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13075-017-1337-6","volume":"19","author":"A Sucur","year":"2017","unstructured":"Sucur A, Jajic Z, Artukovic M, Matijasevic MI, Anic B, Flegar D, et al. Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells. Arthritis Res Ther. 2017;19:142. https:\/\/doi.org\/10.1186\/s13075-017-1337-6","journal-title":"Arthritis Res Ther"},{"key":"1904_CR42","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.bcp.2019.03.029","volume":"165","author":"E Siouti","year":"2019","unstructured":"Siouti E, Andreakos E. The many facets of macrophages in rheumatoid arthritis. Biochem Pharmacol. 2019;165:152\u201369. https:\/\/doi.org\/10.1016\/j.bcp.2019.03.029","journal-title":"Biochem Pharmacol"},{"key":"1904_CR43","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/imcb.12311","volume":"98","author":"J Karami","year":"2020","unstructured":"Karami J, Aslani S, Tahmasebi MN, Mousavi MJ, Sharafat Vaziri A, Jamshidi A, et al. Epigenetics in rheumatoid arthritis; fibroblast-like synoviocytes as an emerging paradigm in the pathogenesis of the disease. Immunol Cell Biol. 2020;98:171\u201386. https:\/\/doi.org\/10.1111\/imcb.12311","journal-title":"Immunol Cell Biol"},{"key":"1904_CR44","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.febslet.2012.02.045","volume":"586","author":"Y Qiao","year":"2012","unstructured":"Qiao Y, Wang P, Qi J, Zhang L, Gao C. TLR-induced NF-kappaB activation regulates NLRP3 expression in murine macrophages. FEBS Lett. 2012;586:1022\u20136. https:\/\/doi.org\/10.1016\/j.febslet.2012.02.045","journal-title":"FEBS Lett"},{"key":"1904_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nature18629","volume":"535","author":"X Liu","year":"2016","unstructured":"Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016;535:153\u20138. https:\/\/doi.org\/10.1038\/nature18629","journal-title":"Nature"},{"key":"1904_CR46","doi-asserted-by":"publisher","first-page":"1228176","DOI":"10.3389\/fimmu.2023.1228176","volume":"14","author":"H Yin","year":"2023","unstructured":"Yin H, Liu N, Sigdel KR, Duan L, Corrigendum. Role of NLRP3 inflammasome in rheumatoid arthritis. Front Immunol. 2023;14:1228176. https:\/\/doi.org\/10.3389\/fimmu.2023.1228176","journal-title":"Front Immunol"},{"key":"1904_CR47","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.4049\/jimmunol.0800909","volume":"182","author":"MT Huang","year":"2009","unstructured":"Huang MT, Taxman DJ, Holley-Guthrie EA, Moore CB, Willingham SB, Madden V, et al. Critical role of apoptotic speck protein containing a caspase recruitment domain (ASC) and NLRP3 in causing necrosis and ASC speck formation induced by porphyromonas gingivalis in human cells. J Immunol. 2009;182:2395\u2013404. https:\/\/doi.org\/10.4049\/jimmunol.0800909","journal-title":"J Immunol"},{"key":"1904_CR48","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1074\/jbc.M112.422238","volume":"288","author":"G Lopez-Castejon","year":"2013","unstructured":"Lopez-Castejon G, Luheshi NM, Compan V, High S, Whitehead RC, Flitsch S, et al. Deubiquitinases regulate the activity of caspase-1 and interleukin-1\u03b2 secretion via assembly of the inflammasome. J Biol Chem. 2013;288:2721\u201333. https:\/\/doi.org\/10.1074\/jbc.M112.422238","journal-title":"J Biol Chem"},{"key":"1904_CR49","doi-asserted-by":"publisher","unstructured":"Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis. 2002;61 Suppl 2:ii84\u20136. https:\/\/doi.org\/10.1136\/ard.61.suppl_2.ii84","DOI":"10.1136\/ard.61.suppl_2.ii84"},{"key":"1904_CR50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.coph.2018.03.006","volume":"40","author":"Y Tanaka","year":"2018","unstructured":"Tanaka Y, Ohira T. Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. Curr Opin Pharmacol. 2018;40:110\u20139. https:\/\/doi.org\/10.1016\/j.coph.2018.03.006","journal-title":"Curr Opin Pharmacol"},{"key":"1904_CR51","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/art.21873","volume":"54","author":"HY Lee","year":"2006","unstructured":"Lee HY, Jeon HS, Song EK, Han MK, Park SI, Lee SI, et al. CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis: evidence of NF-kappaB-dependent, CD40-mediated bone destruction in rheumatoid arthritis. Arthritis Rheum. 2006;54:1747\u201358. https:\/\/doi.org\/10.1002\/art.21873","journal-title":"Arthritis Rheum"},{"key":"1904_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","volume":"12","author":"T Wada","year":"2006","unstructured":"Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12:17\u201325. https:\/\/doi.org\/10.1016\/j.molmed.2005.11.007","journal-title":"Trends Mol Med"},{"key":"1904_CR53","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.yexcr.2006.10.001","volume":"313","author":"K Sundaram","year":"2007","unstructured":"Sundaram K, Nishimura R, Senn J, Youssef RF, London SD, Reddy SV. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res. 2007;313:168\u201378. https:\/\/doi.org\/10.1016\/j.yexcr.2006.10.001","journal-title":"Exp Cell Res"},{"key":"1904_CR54","doi-asserted-by":"publisher","first-page":"45969","DOI":"10.1074\/jbc.M408795200","volume":"279","author":"M Matsumoto","year":"2004","unstructured":"Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem. 2004;279:45969\u201379. https:\/\/doi.org\/10.1074\/jbc.M408795200","journal-title":"J Biol Chem"},{"key":"1904_CR55","doi-asserted-by":"publisher","unstructured":"Takayanagi H. The role of NFAT in osteoclast formation. Ann N Y Acad Sci. 2007; 1116:227\u2009\u2013\u200937. https:\/\/doi.org\/10.1196\/annals.1402.071","DOI":"10.1196\/annals.1402.071"},{"key":"1904_CR56","doi-asserted-by":"publisher","unstructured":"Han G, Zuo J, Holliday LS. Specialized roles for actin in osteoclasts: unanswered questions and therapeutic opportunities. Biomolecules. 2019;9. https:\/\/doi.org\/10.3390\/biom9010017","DOI":"10.3390\/biom9010017"},{"key":"1904_CR57","doi-asserted-by":"publisher","unstructured":"Lee K, Seo I, Choi MH, Jeong D. Roles of Mitogen-activated protein kinases in osteoclast biology. Int J Mol Sci. 2018;19. https:\/\/doi.org\/10.3390\/ijms19103004","DOI":"10.3390\/ijms19103004"},{"key":"1904_CR58","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1042\/bst20190280","volume":"47","author":"ML Stoker","year":"2019","unstructured":"Stoker ML, Newport E, Hulit JC, West AP, Morten KJ. Impact of pharmacological agents on mitochondrial function: a growing opportunity? Biochem Soc Trans. 2019;47:1757\u201372. https:\/\/doi.org\/10.1042\/bst20190280","journal-title":"Biochem Soc Trans"},{"key":"1904_CR59","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.tem.2012.06.006","volume":"23","author":"RC Scarpulla","year":"2012","unstructured":"Scarpulla RC, Vega RB, Kelly DP. Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol Metab. 2012;23:459\u201366. https:\/\/doi.org\/10.1016\/j.tem.2012.06.006","journal-title":"Trends Endocrinol Metab"},{"key":"1904_CR60","doi-asserted-by":"publisher","unstructured":"Larsson NG, Barsh GS, Clayton DA. Structure and chromosomal localization of the mouse mitochondrial transcription factor A gene (tfam). Mamm Genome. 1997;8:139\u201340. https:\/\/doi.org\/10.1007\/s003359900373","DOI":"10.1007\/s003359900373"},{"key":"1904_CR61","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10815-012-9803-1","volume":"29","author":"T Cayci","year":"2012","unstructured":"Cayci T, Kurt YG, Akgul EO, Kurt B. Does mtDNA copy number mean mitochondrial abundance? J Assist Reprod Genet. 2012;29:855. https:\/\/doi.org\/10.1007\/s10815-012-9803-1","journal-title":"J Assist Reprod Genet"},{"key":"1904_CR62","doi-asserted-by":"crossref","unstructured":"Kim M, Choe Y-h, Lee S-i. Lessons from the success and failure of targeted drugs for rheumatoid arthritis: perspectives for effective basic and translational research. Immune Netw. 2022;22","DOI":"10.4110\/in.2022.22.e8"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-024-01904-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-024-01904-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-024-01904-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T21:41:39Z","timestamp":1722030099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-024-01904-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":62,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1904"],"URL":"https:\/\/doi.org\/10.1007\/s00011-024-01904-6","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"4 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}